Current Treatment Protocols:

We have treated hundreds of patients with PAH with long-term intravenous prostacyclin, treprostinil, sildenafil, bosentan, sitaxsentan, ambrisentan, iloprost, and more. We accept referrals from all sources and welcome any interest or questions from health-care workers and from the general public.

LOOK

·     A trial of tadalafil (Cialis) to treat PAH has been completed

·     A trial of ADDING sildenafil (Viagra) to patients already on IV epoprostenol (Flolan) has been completed, results are in!!

·     A new trial of beraprost-Modified Release for patients with PAH will be enrolling in January, 2009.

·     A trial of ambrisentan for patients with PAH is Ongoing.

·     A trial of 2 new oral drugs for patients with PAH will begin in 2009; preliminary results are in.

·     A trial of inhaled Remodulin has been completed, preliminary results are in!!

·     A trial adding bosentan to patients already on sildenafil is ongoing.

·     A trial of ORAL Remodulin is ongoing.

·     Exercise training (rehabilitation) trial: Click HERE for more info.

                  ...and more!



 

Summary of Research Trials at Harbor-UCLA

 

TRIAL

SPONSOR

PLACEBO

PRIMARY ENDPOINT

START DATE

Endothelin antagonist (added to sildenafil)

Actelion

Yes (1 in 2)

clinical worsening

Starting in 2009

Furopyridine

Gilead Sciences

No
("open label")

6-minute walk

Starts in 2009

Oral Prostanoid

LungRx

NO

6-minute walk

Starts in 2009

Endothelin antagonsist

(ambrisentan)

Gileas Sciences

Yes

6-minute walk

Ongoing

Inhaled prostacyclin analogue

LungRx

Yes

6-minute walk

Enrollment complete, sorry

PDE-5 inhibitor

Icos

Yes

6-minute walk

Ended...sorry

Oral Remodulin (prostanoid)

United Therapeutics

Yes

6-minute walk

Enrollment complete, sorry

Exercise rehabilitation (see link above)

NIH/Harbor-UCLA

Yes

multiple

Ongoing

 

 



Conventional PULMONARY ARTERIAL HYPERTENSION TREATMENT

       All patients are given an in-depth medical evaluation and counseled on the risks and benefits of prostacyclin in PAH.

       Initiation of prostacyclin takes approximately two days as an inpatient, and patients are usually ready to return to progressive activities upon discharge. While patients are hospitalized, their families and/or supporting members will be instructed on the use of prostacyclin, how to administer the drug, and what to do in case of an emergency.

For more information on any of the above trials, call our research coordinator, Joy at 310-222-3560


This page has been viewed Counter times